Titan has a broad intellectual property portfolio, with issued patents and patent applications covering formulations, processes and methods related to the ProNeura™ technology platform for the treatment of certain chronic diseases, including opioid addiction and Parkinson's disease.
In June 2010, the United States Patent and Trademark Office (USPTO) issued a patent covering methods of using Probuphine® for the treatment of opiate addiction. Titan is the owner of this patent, which claims a method for treating opiate addiction with a subcutaneously implanted device comprised of buprenorphine and ethylene vinyl acetate co-polymer (EVA), a biocompatible copolymer that releases buprenorphine continuously for extended periods of time. This patent will expire in June 2024.
Related patents covering the use of Probuphine with the continuous delivery technology for the treatment of opiate addiction have also been issued in Australia, Canada, India, Japan, Mexico and New Zealand. Further prosecution of Probuphine applications is currently proceeding at the United States Patent and Trade Office and corresponding agencies in Europe, Canada, India and Hong Kong.
Titan has received notice of allowance for a patent application covering the sustained release of dopamine agonists utilizing ProNeura in the U.S. until at least 2024. Patents covering certain dopamine agonist implants also have already been issued or allowed in Europe, Japan, Australia, Canada, South Korea, Mexico, New Zealand, South Africa and Hong Kong, while prosecution of the patent application continues in Israel, India, Japan and China.